ADAM17 fluorometric drug discovery kit

The ADAM17 Fluorometric (also known as fluorimetric) Drug Discovery Kit is a complete assay system designed to screen ADAM17 (TACE) inhibitors using a quenched fluorogenic peptide: Mca-PLAQAV-Dpa-RSSSR-NH₂. Mca fluorescence is quenched by the Dpa group until cleavage by proteases separates the two moieties. The assays are performed in a convenient 96-well microplate format. The kit is useful to screen inhibitors of ADAM17, a potential therapeutic target. The compound GM6001 is also included as a prototypic control inhibitor.

TACE/ADAM17 (Tumor necrosis factor- α -converting enzyme; A Disintegrin And Metalloproteinase 17) is a soluble or membrane-bound metalloproteinase primarily responsible for activation of proTNF- α , while also targeting proteins such as fractalkine, amyloid precursor proteins, and CD40. ADAM17/TACE is involved in cancer, vascular disorders, and inflammatory diseases such as rheumatoid arthritis and focal ischemic injury. The catalytic domain of ADAM17/TACE is able to cleave proTNF- α and is used in inhibitor screening.

Ordering Information

Order Online »

BML-AK310-0001

96 wells

Manuals, SDS & CofA

View Online »

Handling & Storage

Handling Avoid freeze/thaw cycles.

Long Term Storage -80°C

Shipping Dry Ice

Regulatory Status RUO - Research Use Only

Product Details

Alternative Name TACE, A disintegrin and metalloproteinase 17

Application Activity assay, Fluorescent detection, HTS

Application Notes Designed to screen ADAM17 (TACE) inhibitors using a

quenched fluorogenic peptide.

Contents 1 vial ADAM17 enzyme

1 vial Substrate (Mca-PLAQAV-Dpa-RSSSR-NH₂)

vial CALIBRATION STANDARD
vial control inhibitor (GM6001)
bottle (20 ml) assay buffer
black 96-well microplate

Instructions

UniProt ID P78536

Last modified: May 29, 2024

